Skip to main content

Table 1 Patient characteristics of all included patients stratified by disease severity

From: High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients

 

Overall, N = 47

Disease severity

p-value

Low, N = 38

High, N = 9

Baseline characteristics

Age, years (IQR)

70 (60, 79)

68 (59, 78)

71 (61, 80)

0.53

Male sex, n (%)

31 (66)

23 (61)

8 (89)

0.14

Number of comorbidities

   

 > 0.99

 >  = 2, n (%)

20 (43)

16 (42)

4 (44)

 

0–1, n (%)

27 (57)

22 (58)

5 (56)

 

CCI-score (IQR)

4 (2, 6)

4 (2, 6)

4 (3, 5)

0.81

Immunodeficiency*

0 (0)

0 (0)

0 (0)

 

Clinical characteristics

EWS score at admission (IQR)

5 (3, 7)

5 (2, 6)

6 (5, 7)

0.10

Days since symptom onset at inclusion, days (IQR)

7 (4, 10)

7 (4, 10)

6 (4, 7)

0.24

No assisted respiration, n (%)

9 (19)

9 (24)

0 (0)

0.17

Nasal cannula/mask < 5 L oxygen/min, n (%)

26 (55)

26 (68)

0 (0)

 < 0.001

Mask >  = 5 L oxygen/min, n (%)

3 (6.5)

3 (7.9)

0 (0)

 > 0.99

High-flow oxygen therapy, n (%)

4 (8.5)

0 (0%)

4 (44)

 < 0.001

Respirator, n (%)

3 (6.5)

0 (0)

3 (33)

0.005

NIV, n (%)

2 (4.5)

0 (0)

2 (22)

0.033

Admission length, days (IQR)

5 (3, 10)

4 (3, 7)

19 (11, 30)

 < 0.001

Death during admission, n (%)

2 (4.5)

1 (2.6)

1 (11)

0.35

Death within 180 days, n (%)

3 (6.5)

1 (2.6)

2 (22)

0.090

  1. P-value was calculated using Mann–Whitney U test for numerical variables and Fisher’s exact test for categorical variables
  2. CCI Charlson comorbidity index, EWS Early warning score, NIV Non-invasive ventilation
  3. *Immunodeficiency was defined as: the use of (1) corticosteroid treatment exceeding a prednisolone-equivalent dose of 20 mg daily ≥ 14 days at the time of admission, (2) monoclonal antibodies interfering with the immune system, (3) small molecular immunosuppressants, (4) antineoplastic agents, or (5) a primary immunodeficiency diagnosis